X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. We have successfully developed mavorixafor, receiving U.S. approval for XOLREMDI® (mavorixafor) in its first indication. We are currently advancing  mavorixafor for additional patient populations as well, and have initiated a pivotal, global Phase 3 clinical trial (the 4WARD trial) in people with certain chronic neutropenic disorders.

With a focus on CXCR4 and immune system biology, we continue to leverage our expertise both at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria to further advance our patient-centric mission.

X4 is publicly traded on the Nasdaq Global Market under the symbol: XFOR

Our core values define us and act as guideposts for our thoughts, behaviors, and decisions every day as we strive to innovate for patients.